Magle Chemoswed Holding AB (publ) (MAGLE.ST)
SEK 33.2
(1.84%)
SEK 33.2
(1.84%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 9.96 Million SEK | -92.59% |
| 2022 | 134.38 Million SEK | 21.25% |
| 2021 | 110.83 Million SEK | -0.99% |
| 2020 | 111.94 Million SEK | 7.42% |
| 2019 | 104.2 Million SEK | 11.38% |
| 2018 | 93.56 Million SEK | 5377.99% |
| 2017 | 1.7 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 122 Thousand SEK | -76.26% |
| 2024 Q3 | 58.4 Million SEK | 47775.41% |
| 2024 Q1 | 514 Thousand SEK | -90.54% |
| 2023 FY | 9.96 Million SEK | -92.59% |
| 2023 Q3 | 35.1 Million SEK | -14.8% |
| 2023 Q2 | 41.2 Million SEK | 10.27% |
| 2023 Q1 | 37.36 Million SEK | 1.95% |
| 2023 Q4 | 5.43 Million SEK | -84.52% |
| 2022 Q2 | 38.03 Million SEK | 28.18% |
| 2022 Q1 | 29.67 Million SEK | 54.93% |
| 2022 Q3 | 30.01 Million SEK | -21.08% |
| 2022 FY | 134.38 Million SEK | 21.25% |
| 2022 Q4 | 36.65 Million SEK | 22.09% |
| 2021 Q4 | 19.15 Million SEK | -41.36% |
| 2021 Q3 | 32.66 Million SEK | 3.61% |
| 2021 Q2 | 31.52 Million SEK | 18.9% |
| 2021 Q1 | 26.51 Million SEK | 7.81% |
| 2021 FY | 110.83 Million SEK | -0.99% |
| 2020 Q4 | 24.59 Million SEK | -5.09% |
| 2020 Q2 | 33.69 Million SEK | 33.9% |
| 2020 FY | 111.94 Million SEK | 7.42% |
| 2020 Q1 | 25.16 Million SEK | -42.02% |
| 2020 Q3 | 25.91 Million SEK | -23.1% |
| 2019 Q3 | 16.03 Million SEK | -18.25% |
| 2019 Q4 | 43.4 Million SEK | 170.67% |
| 2019 FY | 104.2 Million SEK | 11.38% |
| 2019 Q2 | 19.61 Million SEK | -16.13% |
| 2019 Q1 | 23.39 Million SEK | 0.0% |
| 2018 FY | 93.56 Million SEK | 5377.99% |
| 2017 FY | 1.7 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 106.2% |
| Ziccum AB (publ) | -23.28 Million SEK | 142.785% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 97.123% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 76.158% |
| Mendus AB (publ) | 28.48 Million SEK | 65.026% |
| Genovis AB (publ.) | 54 Million SEK | 81.55% |
| Intervacc AB (publ) | -13.79 Million SEK | 172.227% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -358.913% |
| Active Biotech AB (publ) | -1.67 Million SEK | 694.806% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 62.854% |
| Aptahem AB (publ) | 2.63 Million SEK | -278.728% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 391.231% |
| Kancera AB (publ) | -1.96 Million SEK | 607.023% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -12838.961% |
| Fluicell AB (publ) | 1.73 Million SEK | -473.245% |
| Saniona AB (publ) | 11.78 Million SEK | 15.432% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 294.704% |
| Biovica International AB (publ) | 6.87 Million SEK | -44.874% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 142.791% |
| AcouSort AB (publ) | 8.38 Million SEK | -18.763% |
| Xintela AB (publ) | 78 Thousand SEK | -12673.077% |
| Abliva AB (publ) | -35.66 Million SEK | 127.937% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 106.782% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -254.934% |
| OncoZenge AB (publ) | 3000.00 SEK | -332000.0% |
| Amniotics AB (publ) | -1.93 Million SEK | 616.218% |
| 2cureX AB (publ) | -37.48 Million SEK | 126.577% |
| CombiGene AB (publ) | -21.29 Million SEK | 146.795% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 2455.319% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.118% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.37% |
| Corline Biomedical AB | 28.38 Million SEK | 64.894% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 108.118% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 128.95% |
| I-Tech AB | 27.56 Million SEK | 63.858% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 85.958% |
| Cyxone AB (publ) | 2.61 Million SEK | -281.578% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -192.771% |
| Biosergen AB | -456 Thousand SEK | 2284.868% |
| Cantargia AB (publ) | -3.45 Million SEK | 388.699% |
| NextCell Pharma AB | -43.74 Million SEK | 122.774% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 208.364% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 11.19% |
| Nanologica AB (publ) | -76 Thousand SEK | 13209.211% |
| SynAct Pharma AB | -778 Thousand SEK | 1380.591% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 5262.176% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 177.101% |
| Lipum AB (publ) | 53 Thousand SEK | -18698.113% |
| BioInvent International AB (publ) | 71.46 Million SEK | 86.058% |
| Alzinova AB (publ) | 19.87 Million SEK | 49.869% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 72.553% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -580.989% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 66520.0% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -500.905% |
| Simris Alg AB (publ) | 2 Million SEK | -396.413% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 378.296% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 71.846% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 1049.762% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -218.002% |